Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | SCN4A | P35499 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408331 | 0.77 | PDK1 (0.59) | LIMK1ALDH1A1PDK1KDM4EHTR2B | |
| SCHEMBL439305 | 0.77 | CDC7 (0.35) | LIMK1ALDH1A1PDK1KDM4E | |
| SCHEMBL441171 | 0.76 | PDK1 (0.36) | DRD2HRH2HRH1DRD3HRH4 | |
| SCHEMBL438511 | 0.74 | SMN1; SMN2 (0.39) | DRD2HRH2HRH1DRD3HRH4 | |
| SCHEMBL463682 | 0.67 | MTNR1A (0.48) | — | |
| SCHEMBL13314816 | 0.63 | RAB9A (0.50) | DRD2HRH2HRH1DRD3HRH4 | |
| SCHEMBL3533425 | 0.63 | RAB9A (0.50) | DRD2HRH2HRH1DRD3HRH4 | |
| SCHEMBL30839548 | 0.62 | ROCK2 (0.38) | DRD2DRD3 | |
| SCHEMBL13314812 | 0.61 | RAB9A (0.47) | ALDH1A1KDM4E | |
| SCHEMBL3538338 | 0.61 | RAB9A (0.47) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | LIMK1 4784/4885DRD2 3020/4885HRH2 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.